States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Marks first international filing for Evofem’s single-dose oral treatment
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda will seek an external partner to leverage its cell therapy platform technologies
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Subscribe To Our Newsletter & Stay Updated
